Clinical Trial ECOGGIS0820


A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Principal Investigator(s)

Emily Chan


  • Protocol No. ECOGGIS0820
  • Open Date: 09/03/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To assess whether eflornithine (+/- sulindac), sulindac (+/- eflornithine) or the combination are effective in reducing the three-year event rate (high-risk adenomas and second primary colorectal cancers) in patients with previously treated Stage 0-III colon cancer.
  • Disease Sites: Colon; Rectal
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Eflornithine; Sulindac
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01349881
  • Secondary Protocol No: S0820



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.